Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man von McKillop, D., Hutchison, M., Partridge, E. A., Bushby, N., Cooper, C. M. F., Clarkson-Jones, J. A., Herron, W., Swaisland, H. C.

Volltext

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib? von Wilson, C.G., O’Mahony, B., Connolly, S.M., Cantarini, M.V., Farmer, M.R., Dickinson, P.A., Smith, R.P., Swaisland, H.C.

Volltext

A sensitive assay for ZD1839 (Iressa ) in human plasma by liquid–liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use... von Jones, H.K, Stafford, L.E, Swaisland, H.C, Payne, R

Volltext

Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog von McKillop, D., Partridge, E. A., Hutchison, M., Rhead, S. A., Parry, A. C., Bardsley, J., Woodman, H. M., Swaisland, H. C.

Volltext

In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers von Swaisland, H. C., Oliver, S. D., Morris, T., Jones, H. K., Bakhtyari, A., Mackey, A., McCormick, A. D., Slamon, D., Hargreaves, J. A., Millar, A., Taboada, M. T.

Volltext

Single-dose clinical pharmacokinetic studies of gefitinib von SWAISLAND, Helen C, SMITH, Robert P, LAIGHT, Alison, KERR, David J, RANSON, Malcolm, WILDER-SMITH, Clive H, DUVAUCHELLE, Thierry

Volltext

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol von SWAISLAND, Helen C, RANSON, Malcolm, SMITH, Robert P, LEADBETTER, Joanna, LAIGHT, Alison, MCKILLOP, David, WILD, Martin J

Volltext

"Studies in Nigerian Administration": (Edited by D.J.Murray) (Book Review) von Swaisland, H C

Volltext

BOOK REVIEWS von SWAISLAND, H. C.

Volltext

NIGERIAN ADMINISTRATION AND ITS POLITICAL SETTING von Swaisland, H. C.

Volltext

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib von Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., Friedlander, M., Gourley, C., Plummer, R., Rustin, G., Sessa, C., Leunen, K., Ledermann, J., Swaisland, H., Fielding, A., Bannister, W., Nicum, S., Molife, L. R.

Volltext

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers von Fong, Peter C, Boss, David S, Yap, Timothy A, Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J, Ashworth, Alan, Carmichael, James, Kaye, Stan B, Schellens, Jan H.M, de Bono, Johann S

Volltext

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Tri... von RANSON, Malcolm, HAMMOND, Lisa A, FEYEREISLOVA, Andrea, SWAISLAND, Helen, ROWINSKY, Eric K, FERRY, David, KRIS, Mark, TULLO, Andrew, MURRAY, Philip I, MILLER, Vince, AVERBUCH, Steve, OCHS, Judy, MORRIS, Charles

Volltext

A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and oth... von El Helali, Aya, Plummer, Ruth, Jayson, Gordon C., Coyle, Vicky M., Drew, Yvette, Mescallado, Nerissa, Harris, Noor, Clamp, Andrew R., McCann, Janine, Swaisland, Helen, Kennedy, Richard D., Cranston, Aaron N., Wilson, Richard H.

Volltext

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules... von Boss, D.S., Schwartz, G.K., Middleton, M.R., Amakye, D.D., Swaisland, H., Midgley, R.S., Ranson, M., Danson, S., Calvert, H., Plummer, R., Morris, C., Carvajal, R.D., Chirieac, L.R., Schellens, J.H.M., Shapiro, G.I.

Volltext

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers von SWAISLAND, Helen, LAIGHT, Alison, STAFFORD, Lesley, JONES, Helen, MORRIS, Charles, DANES, Aaron, YATES, Roger

Volltext

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib von Mateo, J, Moreno, V, Gupta, A, Kaye, S.B, Dean, E, Middleton, M.R, Friedlander, M, Gourley, C, Plummer, R, Rustin, G, Sessa, C, Leunen, Karin, Ledermann, J, Swaisland, H, Fielding, A, Bannister, W, Nicum, S, Molife, L.R

Volltext

417 Human biotransformation of olaparib (AZD2281) an oral poly(ADP-ribose) polymerase (PARP) inhibitor von Clarkson-Jones, J, Page, C, Sarda, S, Swaisland, H

Volltext

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies von Dirix, L, Swaisland, H, Verheul, HMW, Rottey, S, Leunen, K, Jerusalem, G, Rolfo, C, Nielsen, D, Molife, LR, Kristeleit, R, de Vos-Geelen, J, Mau-Sorensen, M, Soetekouw, P, van Herpen, C, Fielding, A, So, K, Bannister, W, Plummer, R

Volltext bestellen

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib von Mateo, J, Moreno, V, Gupta, A, Kaye, SB, Dean, E, Middleton, MR, Friedlander, M, Gourley, C, Plummer, R, Rustin, G, Sessa, C, Leunen, K, Ledermann, J, Swaisland, H, Fielding, A, Bannister, W, Nicum, S, Molife, LR

Volltext bestellen